2026-05-20T04:33:28Zhttps://repisalud.isciii.es/rest/oai/requestoai:repisalud.isciii.es:20.500.12105/204662024-11-28T20:00:56Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16967col_20.500.12105_16971col_20.500.12105_16983
Repisalud
author
Keller, Benjamin
author
Mestre-Pinto, Joan-Ignasi
author
Alvaro-Bartolome, Maria
author
Martinez-Sanvisens, Diana
author
Farre, Magi
author
Julia Garcia-Fuster, M
author
Garcia-Sevilla, Jesus A
author
Torrens, Marta
author
NEURODEP Grp
2024-07-11T09:10:48Z
2024-07-11T09:10:48Z
2017-12-01
Keller B, Mestre-Pinto JI, Alvaro-Bartolome M, Martinez-Sanvisens D, Farre M, García-Fuster MJ, et al. A Biomarker to Differentiate between Primary and Cocaine-Induced Major Depression in Cocaine Use Disorder: The Role of Platelet IRAS/Nischarin (I-1-Imidazoline Receptor). Front Psychiatry. 2017 Dec 01;8:258.
10.3389/fpsyt.2017.00258
1664-0640
Frontiers in Psychiatry
http://hdl.handle.net/20.500.13003/9541
29326609
L619582782
2-s2.0-85037623572
http://hdl.handle.net/20.500.12105/20466
416792100001
The association of cocaine use disorder (CUD) and comorbid major depressive disorder (MDD; CUD/MDD) is characterized by high prevalence and poor treatment outcomes. CUD/MDD may be primary (primary MDD) or cocaine-induced (CUD-induced MDD). Specific biomarkers are needed to improve diagnoses and therapeutic approaches in this dual pathology. Platelet biomarkers [5-HT2A receptor and imidazoline receptor antisera selected (IRAS)/nischarin] were assessed by Western blot in subjects with CUD and primary MDD (n = 16) or CUD-induced MDD (n = 9; antidepressant free, AD-; antidepressant treated, AD+) and controls (n = 10) at basal level and/or after acute tryptophan depletion (ATD). Basal platelet 5-HT2A receptor (monomer) was reduced in comorbid CUD/MDD subjects (all patients: 43%) compared to healthy controls, and this down-regulation was independent of AD medication (decreases in AD-: 47%, and in AD+: 40%). No basal differences were found for IRAS/nischarin contents in AD+ and AD-comorbid CUD/MDD subjects. The comparison of IRAS/nischarin in the different subject groups during/after ATD showed opposite modulations (i.e., increases and decreases) in response to low plasma tryptophan levels with significant differences discriminating between the subgroups of CUD with primary MDD and CUD-induced MDD. These specific alterations suggested that platelet IRAS/nischarin might be useful as a biomarker to discriminate between primary and CUD-induced MDD in this dual pathology.
eng
Platelet biomarker
IRAS/nischarin
Cocaine use disorder
Major depressive disorder
Cocaine-induced depression
Acute tryptophan depletion
Antidepressant drugs
A Biomarker to Differentiate between Primary and Cocaine-Induced Major Depression in Cocaine Use Disorder: The Role of Platelet IRAS/Nischarin (I-1-Imidazoline Receptor)
research article